Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2023-05-25 Declaration of Voting R…
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 25 MAY 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on 25 May 2023. It details the voting outcomes on various resolutions including adoption of financial statements, re-election of directors, appointment of auditors, and approval of amendments to the Memorandum and Articles of Association. The document does not contain the full financial statements or detailed reports but rather the official voting results of the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length (6619 characters) and content confirm it is not a full report or presentation but a formal announcement of voting results. Therefore, the correct classification is DVA with high confidence.
2023-05-25 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on share capital, issued shares, share options, convertibles, and confirmations related to securities issued by Immunotech Biopharm Ltd. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, providing updates on share capital and securities movements rather than financial performance, management changes, or earnings. It does not contain financial statements or management discussion but is a regulatory submission about share capital and securities movements. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-05 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON 25 MAY 2023
AGM Information Classification · 95% confidence The document is a form of proxy for the Annual General Meeting (AGM) of Immunotech Biopharm Ltd scheduled for 25 May 2023. It includes instructions for shareholders to appoint proxies and vote on various resolutions, including adoption of audited financial statements, re-election of directors, appointment of auditors, and amendments to the company's memorandum and articles of association. The content is procedural and related to the conduct of the AGM rather than the actual AGM materials or presentations. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms and voting instructions.
2023-04-25 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice of the Annual General Meeting (AGM) for Immunotech Biopharm Ltd, detailing the date, location, agenda items including adoption of financial statements, re-election of directors, appointment of auditors, and approval of mandates related to share issuance and repurchase. It is clearly labeled as a "NOTICE OF ANNUAL GENERAL MEETING" and contains no actual financial statements or detailed financial analysis, only the agenda and resolutions to be voted on at the AGM. The document is over 12,000 characters, so it is not a brief announcement but the actual notice for the AGM. Therefore, it fits the category of AGM Information (AGM-R) which includes presentations and materials shared during the AGM, including notices of meetings and resolutions to be considered.
2023-04-25 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND
AGM Information Classification · 95% confidence The document is a circular from Immunotech Biopharm Ltd dated 26 April 2023, containing detailed information about the upcoming Annual General Meeting (AGM) scheduled for 25 May 2023. It includes proposals for re-election of retiring directors, granting of general mandates to issue and repurchase shares, amendments to the memorandum and articles of association, and the notice of the AGM itself. The content is typical of materials sent to shareholders ahead of an AGM to inform them of the agenda and resolutions to be voted on. It is not a report of financial results, audit, or earnings, nor is it a transcript or legal proceeding update. It is also not a simple announcement or notice of report publication but a comprehensive circular with detailed proposals and appendices. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-04-25 English
2022 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2022 ANNUAL REPORT' and contains detailed sections typical of an annual report, including Corporate Information, Business and Financial Highlights, Management Discussion and Analysis, Directors and Senior Management, Corporate Governance Report, Financial Summary, Environmental, Social and Governance Report, Independent Auditor’s Report, and detailed financial statements such as Consolidated Statement of Profit or Loss, Statement of Financial Position, Changes in Equity, Cash Flows, and Notes to the Financial Statements. The length is substantial (15,000 characters) and the content includes comprehensive financial data and business analysis for the full fiscal year 2022. This matches the definition of an Annual Report (10-K). FY 2022
2023-04-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.